ABSTRACT
No disponible
Subject(s)
Humans , Injections, Intraperitoneal/instrumentation , Injections, Intraperitoneal/methods , Injections, Intraperitoneal , Anesthesiology/organization & administration , Anesthesiology/standards , Injections, Intraperitoneal/standards , Injections, Intraperitoneal/trends , Anesthesiology/methods , Anesthesiology/trendsABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Injections, Intraperitoneal/instrumentation , Injections, Intraperitoneal/methods , Peritoneal Dialysis/methods , Peritoneal Dialysis/nursing , Dialysis Solutions/therapeutic use , Drug Therapy/methods , Drug Therapy/nursing , Injections, Intraperitoneal/trends , Injections, Intraperitoneal , Peritoneal Dialysis/trends , Peritoneal Dialysis , Dialysis Solutions/administration & dosageABSTRACT
Intraperitoneal chemotherapy provides a means by which high concentrations of drugs and long durations of tissue exposure can be attained at the peritoneal surface. It has been studied widely in ovarian cancer, a disease in which intra-abdominal progression remains the major source of morbidity and mortality. Three large randomized trials have shown improved survival in optimally debulked patients who were treated with intraperitoneal chemotherapy as part of a front-line regimen, yet it has not become part of usual therapy. Several factors have contributed to the reluctance to adopt intraperitoneal therapy, including technical issues related to drug delivery and the fact that all of the large randomized trials employed intraperitoneal cisplatin, which has more toxicity than intravenous carboplatin, the current standard of care. Future research is needed for further definition of the clinical benefit of intraperitoneal chemotherapy, modification of existing regimens to minimize side effects, and exploration of intraperitoneal biologic, immunologic, and gene therapy techniques.
